People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Tangen Biosciences, Inc. | — | Biotechnology | Series A | $28.4M | $4.2M | 2023 |
Richard C. Birkmeyer, PhD at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Richard C. Birkmeyer, PhD on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Dan Wagner | 1 | 4 |
| Christopher McLeod | 1 | 3 |
| Christopher Benoit | 1 | 3 |
| Daniel V. Wagner | 1 | 2 |
| John Davidson | 1 | 2 |
| Christopher V. McLeod | 1 | 1 |
| John V. Davidson | 1 | 1 |
| Brian Chirico | 1 | 1 |
| Richard Birkmeyer, PhD | 1 | 1 |
| John Nobile | 1 | 1 |
| John Richard Nobile | 1 | 1 |
| John Richard Davidson | 1 | 1 |
| Alan V. Levin | 1 | 1 |
| Vance V. Kershner | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.